Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Phillip H. Lam"'
Autor:
Farooq H. Sheikh, Sriram Rao, S. Ahmed, Maria E. Rodrigo, A. Kadakkal, Ezequiel J. Molina, Samer S. Najjar, Mark Hofmeyer, Amiti Jain, Michael Hockstein, Phillip H. Lam
Publikováno v:
Artificial Organs. 46:460-470
BACKGROUND Due to anatomic and physiologic concerns, prior generations of the left ventricular assist devices (LVAD) have frequently been denied to patients with small body size. However, outcomes in patients with small body surface area (BSA) follow
Autor:
Gregg C. Fonarow, Richard M. Allman, Ali Ahmed, Phillip H. Lam, Daniel J. Dooley, Charity J. Morgan, Cherinne Arundel, Deepak L. Bhatt
Publikováno v:
The American Journal of Cardiology. 123:1840-1844
Heart failure (HF) is the leading cause for 30-day all-cause readmission in older Medicare beneficiaries and 30-day all-cause readmission is associated with a higher risk of mortality. In the current analysis, we examined if that association varied b
Autor:
A. Kadakkal, Mark Hofmeyer, Maria E. Rodrigo, Ezequiel J. Molina, Hiroto Kitahara, Farooq H. Sheikh, Samer S. Najjar, S. Ahmed, Phillip H. Lam
Publikováno v:
Journal of Cardiac Surgery. 36:2541-2542
Iatrogenic chordal rupture with severe mitral regurgitation is a rare but serious complication associated with the use of Impella device. We present a case of a 47-year-old man with ischemic cardiomyopathy who required insertion of an Impella 5.0 dev
Publikováno v:
Heart Failure Clinics. 13:581-587
Heart failure is a disease of poor prognosis marked by frequent hospitalizations, premature death, and impaired quality of life. Despite advances in medical therapy for patients with heart failure and reduced ejection fraction, mortality and hospital
Autor:
Phillip H. Lam, Bertram Pitt, Gregg C. Fonarow, Richard M. Allman, Charles Faselis, Steven N. Singh, Milton Packer, Charity J. Morgan, Ali Ahmed
Publikováno v:
The American journal of medicine. 133(2)
Background In the Studies of Left Ventricular Dysfunction (SOLVD) treatment trial, similar clinical benefits were observed between starting doses of enalapril and the target dose achieved by postrandomization up-titration. In our current analysis, pr
Autor:
Kathleen E. Brummel-Ziedins, Matthew Gissel, Eric Gauthier, David J. Schneider, Phillip H. Lam
Publikováno v:
Coronary Artery Disease. 24:468-474
Objective Thrombosis complicating the rupture of an atherosclerotic plaque can lead to arterial occlusion. Tissue factor, a membrane-bound glycoprotein, is expressed to a greater extent in atherosclerotic plaques and may be a key mediator of microthr
Autor:
Ross D. Fletcher, Gregg C. Fonarow, Michel White, Phillip H. Lam, Marc R. Blackman, Rahul Khosla, Cherinne Arundel, Stefan D. Anker, Thomas E. Love, Javed Butler, Qing Zeng, Wilbert S. Aronow, Charity J. Morgan, Prakash Deedwania, Wen-Chih Wu, Richard M. Allman, Ali Ahmed
Publikováno v:
The American journal of medicine. 129(11)
Heart failure is the leading cause for 30-day all-cause readmission. We examined the impact of 30-day all-cause readmission on long-term outcomes and cost in a propensity score-matched study of hospitalized patients with heart failure.Of the 7578 Med
Autor:
Phillip R. Anderson, Burton E. Sobel, Peter VanBuren, Bina Ahmed, Phillip H. Lam, David J. Schneider
Publikováno v:
Coronary artery disease. 22(5)
Background Biomarker expression can predict subsequent cardiovascular events. The goal of this study was to determine the pattern of expression in blood of a broad array of cytokines and growth factors taken 24-72 h after an ST elevation myocardial i